Sangamo Therapeutics Q4 EPS $(0.34) Misses $(0.26) Estimate, Sales $2.04M Miss $8.10M Estimate
Portfolio Pulse from Happy Mohamed
Sangamo Therapeutics (NASDAQ:SGMO) reported Q4 earnings with a per-share loss of $(0.34), missing the $(0.26) estimate, and sales of $2.04M, missing the $8.10M estimate. This represents a significant decrease from the previous year's performance.
March 13, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sangamo Therapeutics reported a larger-than-expected loss per share and a significant miss in sales for Q4, indicating a substantial decrease in performance compared to the previous year.
The reported earnings significantly missed analyst expectations, both in terms of EPS and sales, with a notable decrease from the previous year's figures. This underperformance is likely to negatively impact investor sentiment and could lead to a decrease in SGMO's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100